Post-Operative Pain - Pipeline Review, H1 2014
2014 Jun 30
157 Pages (PDF)
Post-Operative Pain - Pipeline Review, H1 2014 Summary Global Markets Directs, Post-Operative Pain - Pipeline Review, H1 2014, provides an overview of the Post-Operative Pains therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Post-Operative Pain Overview 10 Therapeutics Development 11 Pipeline Products for Post-Operative Pain - Overview 11 Pipeline Products for Post-Operative Pain - Comparative Analysis 12 Post-Operative Pain - Therapeutics under Development by Companies 13 Post-Operative Pain - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Post-Operative Pain - Products under Development by Companies 19 Post-Operative Pain - Companies Involved in Therapeutics Development 21 DURECT Corporation 21 Boehringer Ingelheim GmbH 22 Hospira, Inc. 23 Medtronic, Inc. 24 Terumo Corporation 25 UMeWorld Limited 26 Takeda Pharmaceutical Company Limited 27 Heron Therapeutics, Inc. 28 AcelRx Pharmaceuticals, Inc. 29 Laboratorios Del Dr. Esteve S.A. 30 Orion Corporation 31 Pfizer Inc. 32 A. Menarini Industrie Farmaceutiche Riunite Srl 33 Luitpold Pharmaceuticals, Inc. 34 GW Pharmaceuticals plc 35 AngioChem Inc. 36 Galleon Pharmaceuticals 37 Trevena, Inc. 38 Omeros Corporation 39 Cara Therapeutics, Inc. 40 Encore Therapeutics Inc. 41 Flexion Therapeutics, Inc. 42 Ocular Therapeutix, Inc. 43 Adynxx, Inc. 44 Echo Pharmaceuticals B.V. 45 Recro Pharma, Inc. 46 Post-Operative Pain - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 53 Assessment by Route of Administration 57 Assessment by Molecule Type 60 Drug Profiles 62 ARX-01 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 (ketorolac tromethamine + phenylephrine ) - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 diclofenac sodium - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 bupivacaine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ketorolac tromethamine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 (ketoprofen + amitriptyline + oxymetazoline) - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 (dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 acetaminophen - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 dexamethasone acetate SR - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 nabiximols - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 CR-4056 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 TRV-130 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 CR-845 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 dexmedetomidine hydrochloride - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 RNS-60 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 PF-05089771 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 dronabinol - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 ropivacaine ER - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 E-52862 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 AYX-1 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 fadolmidine hydrochloride - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 AM-4 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 MDT-10013 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 BI-1026706 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 CMX-020 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 VVZ-149 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 ANG-2002 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 ARX-8203 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 FX-007 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 ropivacaine ER - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 buprenorphine hydrochloride ER - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 grapiprant - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 GIBH-1014 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 bupivacaine - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 ropivacaine - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 ARX-8028 - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 GAL-044 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 Post-Operative Pain - Recent Pipeline Updates 116 Post-Operative Pain - Dormant Projects 147 Post-Operative Pain - Discontinued Products 148 Post-Operative Pain - Product Development Milestones 149 Featured News & Press Releases 149 May 07, 2014: Pacira Pharmaceuticals Announces sNDA Submission for EXPAREL Nerve Block Indication 149 May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 149 May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 150 Apr 07, 2014: Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity 151 Apr 04, 2014: EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014 151 Mar 31, 2014: Pacira Pharmaceuticals Announces FDA Approval of Additional Manufacturing Suite for EXPAREL 152 Mar 17, 2014: Antibe Therapeutics Announces Completion of Pre-Clinical Program for ATB-346 152 Mar 17, 2014: Ocular Therapeutix Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone 153 Mar 14, 2014: Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement 153 Mar 12, 2014: Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 154 Appendix 156 Methodology 156 Coverage 156 Secondary Research 156 Primary Research 156 Expert Panel Validation 156 Contact Us 157 Disclaimer 157
DURECT Corporation Boehringer Ingelheim GmbH Hospira, Inc. Medtronic, Inc. Terumo Corporation UMeWorld Limited Takeda Pharmaceutical Company Limited Heron Therapeutics, Inc. AcelRx Pharmaceuticals, Inc. Laboratorios Del Dr. Esteve S.A. Orion Corporation Pfizer Inc. A. Menarini Industrie Farmaceutiche Riunite Srl Luitpold Pharmaceuticals, Inc. GW Pharmaceuticals plc AngioChem Inc. Galleon Pharmaceuticals Trevena, Inc. Omeros Corporation Cara Therapeutics, Inc. Encore Therapeutics Inc. Flexion Therapeutics, Inc. Ocular Therapeutix, Inc. Adynxx, Inc. Echo Pharmaceuticals B.V. Recro Pharma, Inc.